These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10037459)

  • 21. [Aggregation and toxicity of the proteins with polyQ repeats].
    Leźnicki P
    Postepy Biochem; 2005; 51(2):215-22. PubMed ID: 16209359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transglutaminase-dependent formation of protein aggregates as possible biochemical mechanism for polyglutamine diseases.
    Violante V; Luongo A; Pepe I; Annunziata S; Gentile V
    Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):169-72. PubMed ID: 11719247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transglutaminase potentiates ligand-dependent proteasome dysfunction induced by polyglutamine-expanded androgen receptor.
    Mandrusiak LM; Beitel LK; Wang X; Scanlon TC; Chevalier-Larsen E; Merry DE; Trifiro MA
    Hum Mol Genet; 2003 Jul; 12(13):1497-506. PubMed ID: 12812978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transglutaminase is linked to neurodegenerative diseases.
    Muma NA
    J Neuropathol Exp Neurol; 2007 Apr; 66(4):258-63. PubMed ID: 17413316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogenesis of neurodegenerative diseases associated with expanded glutamine repeats: new answers, new questions.
    Ross CA; Margolis RL; Becher MW; Wood JD; Engelender S; Cooper JK; Sharp AH
    Prog Brain Res; 1998; 117():397-419. PubMed ID: 9932422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components.
    Stenoien DL; Mielke M; Mancini MA
    Nat Cell Biol; 2002 Oct; 4(10):806-10. PubMed ID: 12360291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transglutaminase as the agent of neurodegenerative diseases due to polyglutamine expansion.
    Kahlem P; Green H; Djian P
    Pathol Biol (Paris); 1998 Nov; 46(9):681-2. PubMed ID: 9885815
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
    De Vivo G; Di Lorenzo R; Ricotta M; Gentile V
    Curr Med Chem; 2009; 16(36):4767-73. PubMed ID: 19929789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct nuclear localization and activity of tissue transglutaminase.
    Lesort M; Attanavanich K; Zhang J; Johnson GV
    J Biol Chem; 1998 May; 273(20):11991-4. PubMed ID: 9575137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polyglutamine-mediated aggregation and cell death.
    de Cristofaro T; Affaitati A; Feliciello A; Avvedimento EV; Varrone S
    Biochem Biophys Res Commun; 2000 Jun; 272(3):816-21. PubMed ID: 10860836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
    Martin A; Giuliano A; Collaro D; De Vivo G; Sedia C; Serretiello E; Gentile V
    Amino Acids; 2013 Jan; 44(1):111-8. PubMed ID: 21938398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allele-selective suppression of mutant genes in polyglutamine diseases.
    Liu CR; Cheng TH
    J Neurogenet; 2015; 29(2-3):41-9. PubMed ID: 26174158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates.
    de Cristofaro T; Affaitati A; Cariello L; Avvedimento EV; Varrone S
    Biochem Biophys Res Commun; 1999 Jun; 260(1):150-8. PubMed ID: 10381359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Molecular biology of polyglutamine diseases].
    Owecki M; Kozubski W
    Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanded polyglutamine tract itself induces cell death in cultured cells.
    Bok KS; Rhim H; Yoo YD; Choi E; Ahn K; Kim IH; Kang S
    Mol Cells; 1999 Aug; 9(4):398-402. PubMed ID: 10515603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration.
    Citron BA; Suo Z; SantaCruz K; Davies PJ; Qin F; Festoff BW
    Neurochem Int; 2002 Jan; 40(1):69-78. PubMed ID: 11738473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.
    Chun W; Lesort M; Tucholski J; Faber PW; MacDonald ME; Ross CA; Johnson GV
    Neurobiol Dis; 2001 Jun; 8(3):391-404. PubMed ID: 11442349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical mechanisms for a possible involvement of the transglutaminase activity in the pathogenesis of the polyglutamine diseases: minireview article.
    Pepe I; Occhino E; Cella G; Luongo A; Guardascione F; Gentile V
    Amino Acids; 2004 Jul; 26(4):431-4. PubMed ID: 15290350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies.
    Kumada S; Uchihara T; Hayashi M; Nakamura A; Kikuchi E; Mizutani T; Oda M
    J Neuropathol Exp Neurol; 2002 Nov; 61(11):984-91. PubMed ID: 12430715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue transglutaminase: a possible role in neurodegenerative diseases.
    Lesort M; Tucholski J; Miller ML; Johnson GV
    Prog Neurobiol; 2000 Aug; 61(5):439-63. PubMed ID: 10748319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.